Pfizer Temporarily Discontinues Premarin Vaginal Cream in India Due to Supply Challenges
Pfizer has temporarily discontinued Premarin vaginal cream in India due to supply challenges, leaving patients with limited alternatives for treating menopause-related symptoms.
Intelligence analysis by Llama
Pfizer has temporarily discontinued Premarin vaginal cream in India due to supply challenges, leaving patients with limited alternatives for treating menopause-related symptoms. The company is exploring options to resume supply as soon as possible.
Pfizer temporarily stopped selling a special cream in India that helps women with menopause symptoms. This cream is important for many women in India, and now they might not have a good alternative. Pfizer is trying to fix the problem and get the cream back on the market as soon as possible.
Analysis
A Blow to Menopause Treatment in India
The temporary discontinuation of Premarin vaginal cream in India by Pfizer has sent shockwaves through the medical community, leaving patients with limited alternatives for treating menopause-related symptoms. The cream, which contains a mixture of estrogen hormones, is prescribed to treat vaginal dryness, painful intercourse, and other symptoms of menopause caused by declining estrogen levels.
According to data from Pharmarack, a research firm based in Pune, more than 620,000 units of the cream were sold in the 12 months ended June 2026, representing over half of all units sold in the category. The suspension could leave patients with limited alternatives in India, where treatment options for genitourinary syndrome of menopause (GSM) are already scarce.
Dr. Sukhpreet Patel, a gynecologist and founder of MenopauseWize, a menopause education and advocacy platform, said she began hearing complaints from patients late last year that they were unable to obtain Premarin. Initially, she assumed the problem was linked to broader global shortages of hormone therapies. However, the discontinuation of Premarin in India is a separate issue, driven by supply challenges.
The suspension of Premarin vaginal cream in India could have significant implications for the country's menopause treatment landscape. With an estimated 400 million women aged 45 and older by 2026, India is expected to have a large patient population. However, awareness and treatment rates remain low, and the discontinuation of Premarin could exacerbate this issue.
Exploring Alternatives
In the absence of Premarin, patients may be forced to seek alternative treatments, which could be less effective or more expensive. Dr. Patel said that local estrogen therapies are particularly important for patients who do not require or wish to use systemic hormone replacement therapy. However, the availability of these alternatives is limited in India, and patients may be forced to rely on imported products or seek treatment abroad.
The Road Ahead
The temporary discontinuation of Premarin vaginal cream in India is a setback for menopause treatment in the country. However, it also presents an opportunity for the medical community to explore alternative treatments and increase awareness about menopause. With an estimated 400 million women aged 45 and older by 2026, India has a significant patient population, and the discontinuation of Premarin could be a wake-up call for the medical community to address the issue of menopause treatment in the country.
Key points
- Pfizer has temporarily discontinued Premarin vaginal cream in India due to supply challenges.
- The suspension could leave patients with limited alternatives for treating menopause-related symptoms.
- Dr. Sukhpreet Patel, a gynecologist and founder of MenopauseWize, said she began hearing complaints from patients late last year that they were unable to obtain Premarin.
- The discontinuation of Premarin in India is a separate issue, driven by supply challenges, and not linked to broader global shortages of hormone therapies.
- The suspension of Premarin vaginal cream in India could have significant implications for the country's menopause treatment landscape.
If Pfizer is able to resume supply of Premarin vaginal cream in India, it could provide a reliable treatment option for millions of women experiencing menopause-related symptoms. Additionally, the discontinuation of Premarin could lead to increased awareness and treatment of menopause in India, as the medical community explores alternative treatments and increases awareness about the issue.
The temporary discontinuation of Premarin vaginal cream in India could leave patients with limited alternatives for treating menopause-related symptoms, leading to increased suffering and potentially life-altering consequences. Furthermore, the discontinuation could exacerbate the existing issue of low awareness and treatment rates for menopause in India, making it more challenging for patients to access effective treatment.
